First Author: N.Sanduja INDIA
Co Author(s): A. Seth A. Aurora S. Luthra
Back to previous
Choroid plays a vital role in pathophysiology of many retinal conditions. Its role as indicator in the development of Choroidal neovascularisation(CNV) is under evaluation. We conducted this study to evaluate the change in subfoveal retinal and choroidal thickness following three monthly intravitreal injections of ranibizumab in eyes with subfoveal Myopic CNV.
Interventional case series done at Delhi Retina Centre,india
In this interventional case series, 15 eyes with pathological myopia and subfoveal CNV, confirmed on OCT/FFA were included. All eyes were given three monthly injections of Intravitreal ranibizumab 0.3 mg/0.05ml, and were followed up monthly for 3 months with respect to best corrected visual acuity(BCVA), central macular thickness (CMT) and subfoveal choroidal thickness (CT) measured on SD-OCT.
Mean age of patients was 46.3±16.5 years. Mean spherical equivalent (myopia) was 16.22 DS (Range 10-20 DS). Mean baseline BCVA was 0.166±0.12 that improved to 0.378±0.15 at 1 month (p=0.000) and 0.412±0.17 at 3 months (p=0.000). There was a mean improvement of 2.33 lines on Snellen’s acuity chart at 1 month. Mean CMT pre-injection was 319.72±55.4µ that decreased to 253.89±43.59µ at 1 month(p=0.000) and 251.34±47.43µ at 3 months(p=0.000). Mean CT pre-injection was 116.64±44.85µ that decreased to 107.54±44µ at 1 month(p=0.009) and 96.79±35.47µ at 3 month(p=0.001). All 15 eyes showed complete resolution of intraretinal/subretinal edema with scarring of CNV after 3 intravitreal injections of ranibizumab.
Intravitreal ranibizumab decreases choroidal thickness along with retinal thickness, in patients with responsive myopic CNV. Maximum effect is seen at 1 month after first injection. Choroidal thickness might be an indicator of activity of CNV and decreases as CNV heals.